» Articles » PMID: 16551856

Prognostic Relevance of AGR2 Expression in Breast Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2006 Mar 23
PMID 16551856
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We aimed to evaluate the expression of the human anterior gradient-2 (AGR2) in breast cancer on RNA and protein level and to correlate it with clinicopathologic data, including patient survival.

Experimental Design: AGR2 mRNA expression was assessed by reverse transcription-PCR in 25 breast cancer samples and normal tissues. A polyclonal rabbit AGR antiserum was used for immunohistochemistry on 155 clinicopathologically characterized cases. Statistical analyses were applied to test for prognostic and diagnostic associations.

Results: Immunohistochemical detection of AGR2 was statistically significantly associated with positive estrogen receptor status and lower tumor grade. AGR2-positive tumors showed significantly longer overall survival times in univariate analyses. For the subgroup of nodal-negative tumors, an independent prognostic value of AGR2 was found.

Conclusions: The expression of AGR2 in breast cancer is strongly associated with markers of tumor differentiation (estrogen receptor positivity, lower tumor grade). A prognostic effect of AGR2 for overall survival could be shown, which became independently significant for the group of nodal-negative tumors.

Citing Articles

A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17).

Robinson R, Reyes L, Christopher B, Duncan R, Burge R, Siegel J Antibodies (Basel). 2024; 13(4).

PMID: 39727484 PMC: 11672854. DOI: 10.3390/antib13040101.


Prevalence and Significance of AGR2 Expression in Human Cancer.

Schraps N, Port J, Menz A, Viehweger F, Buyucek S, Dum D Cancer Med. 2024; 13(21):e70407.

PMID: 39533806 PMC: 11557986. DOI: 10.1002/cam4.70407.


Prostate cancer research: tools, cell types, and molecular targets.

Liu A Front Oncol. 2024; 14:1321694.

PMID: 38595814 PMC: 11002103. DOI: 10.3389/fonc.2024.1321694.


AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer.

Zhou M, Gan X, Ren Y, Chen Q, Yang Y, Weng Z BMC Cancer. 2023; 23(1):743.

PMID: 37568077 PMC: 10416444. DOI: 10.1186/s12885-023-10964-6.


AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer.

Zhang K, Li Y, Kong X, Lei C, Yang H, Wang N Front Oncol. 2023; 13:1195885.

PMID: 37197416 PMC: 10183570. DOI: 10.3389/fonc.2023.1195885.